Insider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of Stock

Aileron Therapeutics, Inc. (NASDAQ:ALRN) major shareholder Of Texas/Texas Am I. University sold 10,746 shares of Aileron Therapeutics stock in a transaction on Monday, April 29th. The shares were sold at an average price of $4.95, for a total value of $53,192.70. Following the completion of the transaction, the insider now owns 1,799,711 shares in the company, valued at approximately $8,908,569.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aileron Therapeutics Stock Down 1.6 %

Aileron Therapeutics stock opened at $3.76 on Friday. The firm has a fifty day moving average of $5.38 and a 200-day moving average of $3.84. Aileron Therapeutics, Inc. has a 52-week low of $1.01 and a 52-week high of $7.42. The firm has a market capitalization of $63.42 million, a P/E ratio of -1.11 and a beta of 2.32.

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Monday, April 15th. The company reported ($1.54) earnings per share (EPS) for the quarter. On average, research analysts expect that Aileron Therapeutics, Inc. will post -0.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH boosted their target price on Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, April 18th.

Institutional Investors Weigh In On Aileron Therapeutics

An institutional investor recently bought a new position in Aileron Therapeutics stock. Sigma Planning Corp acquired a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned approximately 0.34% of Aileron Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.